A Rollover Study of Sotorasib with or without Panitumumab for the Treatment of Cancer Subjects with KRAS p.G12C Mutation Previously Treated in an Amgen-Sponsored Study.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522355-26-00

Acronym

20250089

Enrollment

Registered

2025-12-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors.

Brief summary

Incidence and severity of treatment-emergent adverse events, clinically significant changes in vital signs, and clinical laboratory tests

Interventions

DRUGPANITUMUMAB

DRUGSOTORASIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence and severity of treatment-emergent adverse events, clinically significant changes in vital signs, and clinical laboratory tests	—

Countries

France, Germany, Greece, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026